# TENNESSEE GENERAL ASSEMBLY FISCAL REVIEW COMMITTEE



# CORRECTED FISCAL NOTE

SB 1205 - HB 1348

March 15, 2021

**SUMMARY OF BILL:** Prohibits a health insurance issuer, a managed health insurance issuer, a pharmacy benefits manager (PBM) or third-party payer from reimbursing a 340B entity for pharmacy-dispensed drugs at a rate lower than that paid for the same drug to pharmacies that are not 340B entities, and from assessing any fee, or other adjustment upon the 340B entity that is not equally assessed on non-340B entities, or exclude a 340B pharmacy from the PBM's or third party's pharmacy network based on criteria that is not applied to non-340B entities.

Prohibits a PBM and third parties from discriminating against a 340B entity or a pharmacy that participates in a health plan as an entity authorized to participate under 42 U.S.C. § 256b in a manner that prevents or interferes with the patient's choice to receive those drugs from the 340B entity.

Effective October 1, 2021, and applies to health plans entered into, executed, issued, amended, delivered, or renewed on or after that date

#### **ESTIMATED FISCAL IMPACT:**

On March 5, 2021, a fiscal note was issued for this legislation estimating a fiscal impact as follows:

Increase State Expenditures –

Exceeds \$3,300/FY21-22
Exceeds \$6,600/FY22-23 and Subsequent Years

Increase Federal Expenditures –

Exceeds \$300/FY21-22 Exceeds \$500/FY22-23 and Subsequent Years

Increase Local Expenditures

Exceeds \$1,200/FY21-22\*
Exceeds \$2,400/FY22-23 and Subsequent Years\*

Based on new information provided by the Division of Benefits Administration, it was determined the estimated fiscal impact was in error. As a result, the estimated fiscal impact has been corrected as follows:

#### (CORRECTED)

#### **NOT SIGNIFICANT**

# Corrected Assumptions:

- Based on information provided by the Division of Benefits Administration, the state group insurance program's PBM does not currently pay a differential rate to 340b filling prescriptions.
- No fiscal impact to state or local government.

# **IMPACT TO COMMERCE:**

Other Commerce Impact – Due to multiple unknown factors, the exact impact to commerce and jobs cannot be reasonably determined.

# Assumption:

• Due to multiple unknown factors, such as negotiated rates with PBMs and 340b entities, current rebate amounts, and specific drug prices, an exact impact to commerce and jobs cannot be reasonably determined.

# **CERTIFICATION:**

The information contained herein is true and correct to the best of my knowledge.

Krista Lee Carsner, Executive Director

Kista Lee Caroner

/vh